CAR T cells induce a complete response in refractory Burkitt Lymphoma
- 24 May 2018
- journal article
- letter
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 53 (12) , 1583-1585
Abstract
No abstract availableThis publication has 12 references indexed in Scilit:
- Chimeric Antigen Receptor T Cells in Refractory B-Cell LymphomasNew England Journal of Medicine, 2017
- Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell LymphomaNew England Journal of Medicine, 2017
- Chimeric antigen receptor T-cell therapy — assessment and management of toxicitiesNature Reviews Clinical Oncology, 2017
- Chimeric antigen receptor T-cell therapies for lymphomaNature Reviews Clinical Oncology, 2017
- Outcomes of adults with relapsed or refractory Burkitt and high‐grade B‐cell leukemia/lymphomaAmerican Journal of Hematology, 2017
- T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trialThe Lancet, 2015
- How I treat Burkitt lymphoma in adultsBlood, 2014
- Chimeric Antigen Receptor T Cells for Sustained Remissions in LeukemiaNew England Journal of Medicine, 2014
- Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic LeukemiaScience Translational Medicine, 2014
- Autologous and Allogeneic Transplantation for Burkitt Lymphoma Outcomes and Changes in Utilization: A Report from the Center for International Blood and Marrow Transplant ResearchTransplantation and Cellular Therapy, 2013